ANGELA PETERSON

Strategic Commercial Leadership & Market Development:

• Serve as the primary lymphoma-focused commercial strategist across a multi-state region, driving adoption of personalized ctDNA MRD testing (Signatera) within major academic and community cancer centers.
• Lead regional business planning, launch strategy, and competitive positioning for lymphoma indications, shaping institutional workflows and influencing decision-making among high-volume lymphoma investigators.
• Build and expand relationships with key lymphoma KOLs across flagship institutions (Mayo Clinic, MD Anderson, University of Chicago, Siteman, KU, Northwestern, MCW), aligning research priorities and accelerating clinical adoption.

Cross-Functional Influence & Operational Excellence:

• Act as the central liaison between cross-functional partners (MSLs, ACOS, market access, operations, and leadership) to ensure seamless onboarding, optimized ordering pathways, and high-quality clinician support.
• Support internal field teams by providing lymphoma-specific expertise, strategic account insights, and clinical evidence interpretation to elevate execution and expand utilization opportunities.
• Serve as the lymphoma-focused commercial strategist across a multi-state region, driving adoption of personalized ctDNA MRD testing (Signatera) within major academic and community cancer centers.

Clinical Evidence Translation & Thought Leadership:

• Integrate emerging data from ASH/ASCO, NCCN updates, and peer-reviewed publications into targeted messaging frameworks that differentiate Signatera and expand testing within aggressive and indolent lymphoma subtypes.
• Lead sophisticated clinical value conversations with oncologists, guiding MRD-driven decision-making and building the rationale for longitudinal monitoring across complex lymphoma cases.
• Collaborated with clinical and commercial teams to align strategic initiatives, driving effective market access for lymphoma therapies.

Strategic Market Expansion & Sales Leadership:

• Led the commercialization of a multi-omics tumor profiling assay, driving adoption from 0 to 120+ tests per quarter, with a 30% growth in ordered tests within the region under management.
• Expanded the market presence from a four-state territory to managing half of the U.S. and an international distributor in Turkey, significantly increasing revenue and brand visibility.
• Built and led a high-performing sales team that scaled to 8 members, surpassing sales targets with a 5% productivity boost and driving market expansion.

Biopharma Business Development & Research Collaborations:

• Secured over $6.9M in research revenue and drove $9M in total regional research revenue over the 1.5 years by shifting focus from clinical oncology assays to research collaborations with MDACC, Mayo Clinic, University of Chicago, and DFCI.
• Developed and executed strategies to integrate BostonGene’s AI-powered bioinformatics and multi-omics clinical testing solutions into drug development, biomarker discovery, and immunoprofiling initiatives.
• Fostered relationships with high-profile pharmaceutical clients, managing long sales cycles and closing multi-year, high-value contracts that expanded the adoption of BostonGene’s solutions.

Cross-Functional Leadership & Go-to-Market Strategy:

• Spearheaded go-to-market strategy for AI-driven bioinformatics and wet lab services, positioning BostonGene as a preferred partner for pharma and biotech companies.
• Influenced corporate strategy, marketing buildout, sales training, and business development in a fast-paced, cross-functional startup environment, contributing to company growth and market positioning.
• Played a pivotal role in branding initiatives, including marketing content development and voiceover work for promotions.
• Biotechnology startup specializing in advanced computational biology and precision medicine.

Sales Growth & Market Expansion:

• Exceeded sales quotas, achieving 110% of the target in 2019 and 105% in 2020, despite industry-wide disruptions.
• Drove 23% territory sales growth within the first year, earning 2019 “Rookie of the Year” honors.
• Recovered from a 68% COVID-driven sales deficit, closing the year at 98% of the total target through adaptive strategies.

Strategic Initiatives & Customer Engagement:

• Developed and executed innovative outreach programs, including a team-wide email project and a territory-wide navigator call, optimizing client engagement during the pandemic.
• Strengthened customer relationships by leveraging a consultative approach to oncology diagnostics and molecular testing.
• Supported the Oncotype MAP Pan-Cancer Tumor Tissue Test pilot program, contributing to early-stage market adoption.

• New Market Development & Product Launch:
• Launched a new-to-market blood-based colorectal cancer recurrence assay, building a territory from 0 to 12 accounts in the Central U.S.
• Secured 52 test orders within the first six months and 156 in 2018, driving adoption despite challenges with NCCN guidelines and reimbursement.
• Established key partnerships, including the University of Kansas Cancer Center, engaging key opinion leaders and driving clinical trial participation.
• Revenue Growth & Competitive Positioning:
• Ranked #3 out of 12 sales representatives for 2017 and 2018, consistently outperforming peers in a competitive market.
• Executed targeted sales strategies to drive the utilization of liquid biopsy technology among oncology specialists.
• Exceeded MBO expectations, demonstrating strong business acumen and a track record of results-driven execution.

• Revenue Growth & Market Expansion:
• Grew annual sales from $1.9M to $3M, driving a 58% revenue increase over 5 years through strategic account penetration.
• Exceeded quotas, achieving 105% in 2016, 95% in 2015, and 120% in 2014, and consistently ranking in the top 20% of the sales force as a recognized hereditary cancer expert.
• Expanded the Genetic Counselor business by 56%, enhancing partnerships and the utilization of hereditary cancer testing.
• Strategic Account Management & Institutional Access:
• Secured $3M in annual revenue by successfully navigating institutional barriers and gaining access to key healthcare centers.
• Built and maintained high-value relationships with oncologists, genetic counselors, and hospital administrators, driving the adoption of precision medicine solutions.
• Developed tailored educational initiatives to enhance client engagement and drive market-leading genetic testing adoption.
• Cultivated strong relationships with healthcare providers, enhancing client satisfaction and fostering long-term partnerships within the genetic testing sector.
• Drove strategic sales initiatives by analyzing market trends and identifying new business opportunities, resulting in increased market share.
• Collaborated with cross-functional teams to streamline workflows and optimize service delivery, improving operational efficiency across the organization.
• Developed and implemented training programs for junior staff, enhancing team performance and ensuring compliance with industry standards.

• Ranked in the top 10% of a 200-member Women’s Health Care sales force for consistently exceeding targets.
• Increased market share by 3% in 2011, surpassing dominant competitors in total script volume.
• Drove the #1 prescription status for key products in the territory, securing market share for portfolio products.
• Launched Lo Loestrin Fe, executing physician education strategies that contributed to rapid market adoption.
• Strengthened relationships with healthcare professionals, driving sales growth through consultative engagement.
• Effectively navigated payer and formulary challenges, ensuring broad access and increasing prescription volume.
• Cultivated strong relationships with healthcare professionals, enhancing product knowledge and driving increased brand loyalty within the territory.
• Delivered comprehensive product presentations to medical staff, effectively conveying complex information and improving prescription rates.
• Collaborated with cross-functional teams to develop targeted marketing strategies, increasing market penetration and brand visibility in competitive landscapes.
• Analyzed sales data to identify trends and customer needs, facilitating informed decision-making and driving revenue growth across multiple product lines.